59 results
424B5
ESPR
Esperion Therapeutics Inc.
22 Jan 24
Prospectus supplement for primary offering
6:04am
, which may be offset by certain U.S. source capital losses of the non-U.S. holder, if any (even though the individual is not considered a resident
424B5
ESPR
Esperion Therapeutics Inc.
18 Jan 24
Prospectus supplement for primary offering
4:01pm
be offset by certain U.S. source capital losses of the non-U.S. holder, if any (even though the individual is not considered a resident of the United States
8-K
EX-99.1
dszr al1nt1w7jl
1 Aug 23
Esperion Reports Second Quarter 2023 Financial Results
7:07am
8-K
EX-99.1
7ks88tv41f
1 Nov 22
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
7:23am
8-K
EX-99.1
6zifg2d4t5pp13w
2 Aug 22
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
7:24am
S-3ASR
w3or7 lpfgvqi
3 Aug 21
Automatic shelf registration
11:05am
RW
ge8q6vdt16x
3 Aug 21
Registration withdrawal request
11:04am